Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem - PubMed
Clinical Trial
. 2000 Dec;22(12):1443-61.
doi: 10.1016/s0149-2918(00)83043-x.
Affiliations
- PMID: 11192136
- DOI: 10.1016/s0149-2918(00)83043-x
Free article
Clinical Trial
Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem
D Drover et al. Clin Ther. 2000 Dec.
Free article
Abstract
Objective: This study compared the pharmacokinetics, pharmacodynamics, and pharmacokinetic/pharmacodynamic (PK/PD) profile of zaleplon, a new pyrazolopyrimidine hypnotic, with those of zolpidem and placebo.
Methods: This was a double-blind, 5-period crossover study in which healthy volunteers with no history of sleeping disorder were randomized to 10- or 20-mg oral doses of zaleplon, 10- or 20-mg oral doses of zolpidem, or placebo. The pharmacokinetic characteristics of the active drugs were estimated using a noncompartmental method and NONMEM. Pharmacodynamic characteristics were determined using psychophysical tests, including measures of sedation, mood, mental and motor speed, and recent and remote recall. Results of these tests were used to compare the drugs' relative PK/PD profiles.
Results: Ten healthy male and female volunteers, aged 23 to 31 years, took part in the study. The apparent elimination half-life of zaleplon (60.1+/-8.9 min) was significantly shorter than that of zolpidem (124.5+/-37.9 min) (P < 0.001). Zaleplon produced less sedation than zolpidem at the 2 doses studied (P < 0.001). The sedation scores of the zaleplon groups returned to baseline in less time than those of the zolpidem groups (4 vs 8 hours; P < 0.05). Zaleplon had no effect on recent or remote recall, whereas zolpidem had a significant effect on both measures (P < 0.05).
Conclusions: In this study in 10 young, healthy volunteers, zaleplon was eliminated more rapidly, produced no memory loss, and caused less sedation than zolpidem at the same doses.
Similar articles
-
Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo.
Greenblatt DJ, Harmatz JS, von Moltke LL, Ehrenberg BL, Harrel L, Corbett K, Counihan M, Graf JA, Darwish M, Mertzanis P, Martin PT, Cevallos WH, Shader RI. Greenblatt DJ, et al. Clin Pharmacol Ther. 1998 Nov;64(5):553-61. doi: 10.1016/S0009-9236(98)90139-4. Clin Pharmacol Ther. 1998. PMID: 9834048 Clinical Trial.
-
Drover DR. Drover DR. Clin Pharmacokinet. 2004;43(4):227-38. doi: 10.2165/00003088-200443040-00002. Clin Pharmacokinet. 2004. PMID: 15005637 Review.
-
Troy SM, Lucki I, Unruh MA, Cevallos WH, Leister CA, Martin PT, Furlan PM, Mangano R. Troy SM, et al. J Clin Psychopharmacol. 2000 Jun;20(3):328-37. doi: 10.1097/00004714-200006000-00007. J Clin Psychopharmacol. 2000. PMID: 10831020 Clinical Trial.
-
Verster JC, Volkerts ER, Schreuder AH, Eijken EJ, van Heuckelum JH, Veldhuijzen DS, Verbaten MN, Paty I, Darwish M, Danjou P, Patat A. Verster JC, et al. J Clin Psychopharmacol. 2002 Dec;22(6):576-83. doi: 10.1097/00004714-200212000-00007. J Clin Psychopharmacol. 2002. PMID: 12454557 Clinical Trial.
-
Clinically important drug interactions with zopiclone, zolpidem and zaleplon.
Hesse LM, von Moltke LL, Greenblatt DJ. Hesse LM, et al. CNS Drugs. 2003;17(7):513-32. doi: 10.2165/00023210-200317070-00004. CNS Drugs. 2003. PMID: 12751920 Review.
Cited by
-
Insomnia in children: when are hypnotics indicated?
Younus M, Labellarte MJ. Younus M, et al. Paediatr Drugs. 2002;4(6):391-403. doi: 10.2165/00128072-200204060-00006. Paediatr Drugs. 2002. PMID: 12038875 Review.
-
Zaleplon (Sonata) oral sedation for outpatient third molar extraction surgery.
Ganzberg SI, Dietrich T, Valerin M, Beck FM. Ganzberg SI, et al. Anesth Prog. 2005 Winter;52(4):128-31. doi: 10.2344/0003-3006(2005)52[128:ZOS]2.0.CO;2. Anesth Prog. 2005. PMID: 16596911 Free PMC article. Clinical Trial.
-
Willner N, Schiff E. Willner N, et al. EXCLI J. 2014 May 6;13:454-6. eCollection 2014. EXCLI J. 2014. PMID: 26417273 Free PMC article. No abstract available.
-
Benefit-risk assessment of zaleplon in the treatment of insomnia.
Barbera J, Shapiro C. Barbera J, et al. Drug Saf. 2005;28(4):301-18. doi: 10.2165/00002018-200528040-00003. Drug Saf. 2005. PMID: 15783240 Review.
-
Development and characterization of zaleplon solid dispersion systems: a technical note.
Waghmare A, Pore Y, Kuchekar B. Waghmare A, et al. AAPS PharmSciTech. 2008;9(2):536-43. doi: 10.1208/s12249-008-9077-1. Epub 2008 Apr 9. AAPS PharmSciTech. 2008. PMID: 18431649 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources